Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

298 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sustained Remission Without Corticosteroids Among Patients With Pemphigus Who Had Rituximab as First-Line Therapy: Follow-Up of the Ritux 3 Trial.
Tedbirt B, Maho-Vaillant M, Houivet E, Mignard C, Golinski ML, Calbo S, Prost-Squarcioni C, Labeille B, Picard-Dahan C, Chaby G, Richard MA, Tancrede-Bohin E, Duvert-Lehembre S, Delaporte E, Bernard P, Caux F, Alexandre M, Musette P, Ingen-Housz-Oro S, Vabres P, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bédane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Benichou J, Joly P, Hébert V; French Reference Center for Autoimmune Blistering Diseases MALIBUL. Tedbirt B, et al. Among authors: alexandre m. JAMA Dermatol. 2024 Mar 1;160(3):290-296. doi: 10.1001/jamadermatol.2023.5679. JAMA Dermatol. 2024. PMID: 38265821 Clinical Trial.
Rituximab for patients with refractory mucous membrane pemphigoid.
Le Roux-Villet C, Prost-Squarcioni C, Alexandre M, Caux F, Pascal F, Doan S, Brette MD, Soued I, Gabison É, Aucouturier F, Letestu R, Laroche L, Bachelez H. Le Roux-Villet C, et al. Among authors: alexandre m. Arch Dermatol. 2011 Jul;147(7):843-9. doi: 10.1001/archdermatol.2011.54. Epub 2011 Mar 21. Arch Dermatol. 2011. PMID: 21422323
Pemphigus in elderly adults: clinical presentation, treatment, and prognosis.
Ingen-Housz-Oro S, Alexandre M, Le Roux-Villet C, Picard-Dahan C, Tancrède-Bohin E, Wallet-Faber N, Mahé E, Begon E, Francès C, Sigal M, Grootenboer-Mignot S, Aucouturier F, André C, Wolkenstein P, Chosidow O, Prost-Squarcioni C. Ingen-Housz-Oro S, et al. Among authors: alexandre m. J Am Geriatr Soc. 2012 Jun;60(6):1185-7. doi: 10.1111/j.1532-5415.2012.03987.x. J Am Geriatr Soc. 2012. PMID: 22690997 No abstract available.
Oral cyclophosphamide without corticosteroids to treat mucous membrane pemphigoid.
Munyangango EM, Le Roux-Villet C, Doan S, Pascal F, Soued I, Alexandre M, Heller M, Lièvre N, Aucouturier F, Caux F, Laroche L, Prost-Squarcioni C. Munyangango EM, et al. Among authors: alexandre m. Br J Dermatol. 2013 Feb;168(2):381-90. doi: 10.1111/bjd.12041. Br J Dermatol. 2013. PMID: 22963186
Calculation of cut-off values based on the Autoimmune Bullous Skin Disorder Intensity Score (ABSIS) and Pemphigus Disease Area Index (PDAI) pemphigus scoring systems for defining moderate, significant and extensive types of pemphigus.
Boulard C, Duvert Lehembre S, Picard-Dahan C, Kern JS, Zambruno G, Feliciani C, Marinovic B, Vabres P, Borradori L, Prost-Squarcioni C, Labeille B, Richard MA, Ingen-Housz-Oro S, Houivet E, Werth VP, Murrell DF, Hertl M, Benichou J, Joly P; International Pemphigus Study Group. Boulard C, et al. Br J Dermatol. 2016 Jul;175(1):142-9. doi: 10.1111/bjd.14405. Epub 2016 Apr 3. Br J Dermatol. 2016. PMID: 26800395 Free article.
Comparison of 3 type VII collagen (C7) assays for serologic diagnosis of epidermolysis bullosa acquisita (EBA).
Seta V, Aucouturier F, Bonnefoy J, Le Roux-Villet C, Pendaries V, Alexandre M, Grootenboer-Mignot S, Heller M, Lièvre N, Laroche L, Caux F, Titeux M, Hovnanian A, Prost-Squarcioni C. Seta V, et al. Among authors: alexandre m. J Am Acad Dermatol. 2016 Jun;74(6):1166-72. doi: 10.1016/j.jaad.2016.01.005. Epub 2016 Mar 3. J Am Acad Dermatol. 2016. PMID: 26947449
Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults.
Gottlieb J, Ingen-Housz-Oro S, Alexandre M, Grootenboer-Mignot S, Aucouturier F, Sbidian E, Tancrede E, Schneider P, Regnier E, Picard-Dahan C, Begon E, Pauwels C, Cury K, Hüe S, Bernardeschi C, Ortonne N, Caux F, Wolkenstein P, Chosidow O, Prost-Squarcioni C. Gottlieb J, et al. Among authors: alexandre m. Br J Dermatol. 2017 Jul;177(1):212-222. doi: 10.1111/bjd.15244. Epub 2017 May 15. Br J Dermatol. 2017. PMID: 27995619
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial.
Joly P, Maho-Vaillant M, Prost-Squarcioni C, Hebert V, Houivet E, Calbo S, Caillot F, Golinski ML, Labeille B, Picard-Dahan C, Paul C, Richard MA, Bouaziz JD, Duvert-Lehembre S, Bernard P, Caux F, Alexandre M, Ingen-Housz-Oro S, Vabres P, Delaporte E, Quereux G, Dupuy A, Debarbieux S, Avenel-Audran M, D'Incan M, Bedane C, Bénéton N, Jullien D, Dupin N, Misery L, Machet L, Beylot-Barry M, Dereure O, Sassolas B, Vermeulin T, Benichou J, Musette P; French study group on autoimmune bullous skin diseases. Joly P, et al. Among authors: alexandre m. Lancet. 2017 May 20;389(10083):2031-2040. doi: 10.1016/S0140-6736(17)30070-3. Epub 2017 Mar 22. Lancet. 2017. PMID: 28342637 Clinical Trial.
298 results